Article
Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.
Antiviral therapy - 1 Jan 2020
Chayanupatkul Maneerat, Chittmittraprap Salyavit, Pratedrat Pornpitra, Chuaypen Natthaya, Avihingsanon Anchalee, Tangkijvanich Pisit
Abstract excerpt
BACKGROUND: The combination of elbasvir and grazoprevir (EBR/GZR) has been approved for treating HCV infection. This study aimed to evaluate the efficacy of EBR/GZR in terms of sustained virological response (SVR) and improvement of liver fibrosis in Thai patients with HCV genotype-1 (GT1). The utility of serum HCV core antigen (HCVcAg) as an alternative to HCV RNA in assessing SVR was also investigated. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.